Alpha 2.0
Login Register
» Articles » PMID: 35834732

Phase 1b, Open-label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (anti-PD-L1 Antibody) Administered in Combination with Hu5F9-G4 to Patients with Relapsed And/or Refractory Acute Myeloid Leukemia

Overview
Journal Leuk Lymphoma
Specialties Hematology
Oncology
Date 2022 Jul 14
PMID 35834732
Authors
Naval Daver
Brian A Jonas
Bruno C Medeiros
Upen Patil
Mark Yan
Affiliations
Soon will be listed here.
Citing Articles

BCL9 is a Risk Factor of Neck Lymph Nodes Metastasis and Correlated with Immune Cell Infiltration in Papillary Thyroid Carcinoma.

Zhang R, Gui Z, Zhao J, Zhao L Int J Gen Med. 2024; 17:1451-1466.

PMID: 38645401 PMC: 11032164. DOI: 10.2147/IJGM.S455846.

The cross-talk between macrophages and tumor cells as a target for cancer treatment.

Aizaz M, Khan A, Khan F, Khan M, Musad Saleh E, Nisar M Front Oncol. 2023; 13:1259034.

PMID: 38033495 PMC: 10682792. DOI: 10.3389/fonc.2023.1259034.

Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with disruptions.

Patel S, cerny J, Gerber W, Ramanathan M, Ediriwickrema A, Tanenbaum B EJHaem. 2023; 4(4):1059-1070.

PMID: 38024632 PMC: 10660125. DOI: 10.1002/jha2.791.

Progress of research on PD-1/PD-L1 in leukemia.

Cao H, Wu T, Zhou X, Xie S, Sun H, Sun Y Front Immunol. 2023; 14:1265299.

PMID: 37822924 PMC: 10562551. DOI: 10.3389/fimmu.2023.1265299.

Macrophage-Based Therapeutic Strategies in Hematologic Malignancies.

Khalili S, Zeinali F, Moghadam Fard A, Taha S, Fazlollahpour Naghibi A, Bagheri K Cancers (Basel). 2023; 15(14).

PMID: 37509382 PMC: 10378576. DOI: 10.3390/cancers15143722.